Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11465304 | 0.78 | TSHR (0.54) | TSHRBCHEOPRM1OPRD1OPRK1 | |
| SCHEMBL4535810 | 0.77 | TSHR (0.58) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL3510726 | 0.77 | CA1 (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL9575541 | 0.76 | TSHR (0.56) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL9972154 | 0.76 | TSHR (0.47) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL2248674 | 0.76 | TSHR (0.47) | TSHRBCHE | |
| SCHEMBL22633329 | 0.74 | CA1 (0.47) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL14296885 | 0.74 | CA1 (0.47) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL12918861 | 0.74 | TSHR (0.45) | TSHROPRM1OPRD1OPRK1 | |
| SCHEMBL10038814 | 0.73 | TSHR (0.44) | TSHRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9402914-B2 | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9402914-B2 | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9402914-B2 | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150165058-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2015-06-18 | — | — | US | disclosed |
| US-20150165058-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2015-06-18 | — | — | US | disclosed |
| US-20150165058-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2015-06-18 | — | — | US | disclosed |
| US-8901101-B2 | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901101-B2 | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901101-B2 | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130289207-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2013-10-31 | — | — | US | disclosed |
| US-20130289207-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2013-10-31 | — | — | US | disclosed |
| US-20130289207-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2013-10-31 | — | — | US | disclosed |
| WO-2012082574-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150165058-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | PUF60, PHOSPHO1, PARG | TSHR 1850/4885CA1 3486/4885CA2 3434/4885 |
| US-20130289207-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | PUF60, PHOSPHO1, PARG | TSHR 1850/4885CA1 3486/4885CA2 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.